Spyre Therapeutics, Inc. (SYRE): Nasdaq/NYSE listing notice — Aeglea BioTherapeutics receives Nasdaq minimum bid price deficiency notice; 180-day cure period to July 12, 2023

Spyre Therapeutics, Inc.

Received Nasdaq notice on Jan 13, 2023 for closing bid price below $1.00 for 30 consecutive trading days.
Must regain compliance by July 12, 2023 with bid price >= $1.00 for at least 10 consecutive days.
If not compliant by July 12, may transfer to Nasdaq Capital Market for an additional 180-day cure period.
No immediate effect on listing; company intends to monitor bid price and consider options.
Failure to regain compliance could result in delisting subject to appeal rights.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Spyre Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

January 13, 2023, Aeglea BioTherapeutics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000840

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.